Advertisement.

CRVO Projected Dividend Yield

CervoMed Inc ( NASDAQ : CRVO )

CervoMed is a clinical stage biotechnology company. Co. is developing its primary product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC). TSC is designed to selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in various indications, including stroke, oncology and cardiovascular disease. Co.'s oncology program targets TSC against treatment-resistant brain cancer. In addition to the TSC programs, Co. is exploring alternatives to capitalize upon its product candidate RES-529, a PI3K/Akt/mTOR pathway inhibitor for age-related macular degeneration.

20 YEAR PERFORMANCE RESULTS

CRVO Dividend History Detail
CRVO Dividend News
CRVO Competitors News

# of Shares: 0

Closing Price: 1.90

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000